Abstract
In 2022, several clinical trials have answered important research questions about revascularisation, and about the indications for endovascular thrombectomy, but their answers have raised additional questions. For example, two multicentre, open-label, randomised trials (DIRECT-SAFE and SWIFT-DIRECT)1,2 compared endovascular thrombectomy alone with combined intravenous thrombolysis and endovascular thrombectomy to find out if intravenous alteplase could be withheld in patients with large vessel occlusion who present directly to a hospital at which endovascular thrombectomy can be done (referred to as mothership patients).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
